Remedium Lifecare’s board of directors has approved the Memorandum of Understanding (MoU) for the proposed merger of MVK Lifesciences (MVK) into the Company for strategic reasons. The proposed merger would be in the best interest of the Parties and their respective shareholders, employees, creditors and other stakeholders as the proposed merger will yield advantages i.e. pooling of resources, achieving economies of scale creating better synergies and long-term sustainability of the business, backward integration of manufacturing facility leading to overall growth of business, create value for stakeholders including respective shareholders, customers, lenders and employees as the combined business would benefit from increased scale, innovations in technology and expanded reach with increased growth opportunities, higher cross selling opportunities to a larger base of customers, improvement in productivity and operational efficiencies, amongst others and greater ability of the company to raise financial resources, either as equity or debt, based on combined financials. The Board of Directors at its meeting held on November 14, 2022 has approved the same.
Remedium Lifecare is pharmaceutical company aligned across two business verticals viz. Products and Services.
Company Name | CMP |
---|---|
Redington | 245.50 |
Adani Enterprises | 2351.30 |
Amrapali Industries | 17.33 |
Rashi Peripheral | 294.25 |
Prithvi Exchange (I) | 167.90 |
View more.. |